GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. (NASDAQ: GLYC) announced today that new preclinical research on tumor growth and metastases and the potential value of its newest drug candidate, GMI-1359, will be presented at the American Association for Cancer Research (AACR) Annual Meeting 2015 in Philadelphia.
Help employers find you! Check out all the jobs and post your resume.
